Palvella Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Palvella Therapeutics Inc.: Is Infosys Ltd. worth buying?
Item: Palvella Therapeutics Inc.
Rating: 1.49366675
Author: Trendlyne DVM scores

about

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin...

113.10 0.47 (0.42%)

25.19% Fall from 52W High

383.2K

XNAS Volume

XNAS 18 Jun, 2026 5:30 PM (EDT)

Not Eligible

Expensive Valuation

3.7 / 100

Technically Neutral

56.1 / 100

No estimates available

Palvella Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Palvella Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin...

25.19% Fall from 52W High

SWOT Analysis

Palvella Therapeutics Inc Live Price Chart